|1.||Leppla, Stephen H: 29 articles (10/2015 - 02/2002)|
|2.||Liu, Shihui: 16 articles (10/2015 - 02/2002)|
|3.||Moayeri, Mahtab: 12 articles (03/2015 - 02/2002)|
|4.||Collier, R John: 11 articles (06/2013 - 01/2002)|
|5.||Quinn, Conrad P: 7 articles (05/2015 - 05/2006)|
|6.||Chen, Wei: 7 articles (05/2015 - 03/2006)|
|7.||Crown, Devorah: 7 articles (03/2015 - 01/2008)|
|8.||Duesbery, Nicholas S: 6 articles (01/2011 - 03/2002)|
|9.||Frankel, Arthur E: 6 articles (06/2008 - 08/2002)|
|10.||Young, John A T: 6 articles (01/2008 - 02/2003)|
01/01/2012 - "In an effort to develop an improved anthrax vaccine that shows high potency, five different anthrax protective antigen (PA)-adjuvant vaccine formulations that were previously found to be efficacious in a nonhuman primate model were evaluated for their efficacy in a rabbit pulmonary challenge model using Bacillus anthracis Ames strain spores. "
10/01/2005 - "14:1673-1682, 2003) that a single administration of a recombinant serotype 5 adenovirus (Ad) vector expressing anthrax protective antigen (PA) provides rapid protection against anthrax lethal toxin challenge. "
05/28/2004 - "The high affinity of the VWA domain for PA supports its potency in neutralizing anthrax toxin, demonstrating its potential utility as a novel therapeutic for anthrax."
02/01/1992 - "The protective efficacy of immunization against anthrax with Bacillus anthracis protective antigen (PA) combined with different adjuvants was tested in Hartley guinea pigs and CBA/J and A/J mice. "
12/01/1995 - "The efficacy of several human anthrax vaccine candidates comprised of different adjuvants together with Bacillus anthracis protective antigen (PA) was evaluated in guinea pigs challenged by an aerosol of virulent B. "
02/01/1987 - "Studies of the number of immunocompetent cells with receptors to anthrax protective antigen in the blood of hamadryas baboons infected with Bacillus anthracis carried out by the rosette-formation technique have shown a statistically significant increase in the number of these cells in the animals as early as 12 hrs after their infection."
11/06/2015 - "Anthrax toxin is a tripartite virulence factor produced by Bacillus anthracis during infection. "
01/01/2014 - "Anthrax lethal factor inhibitors as potential countermeasure of the infection."
01/04/2012 - "CMG2 is the main receptor of the anthrax toxin, and knocking out this gene in mice renders them insensitive to infection with Bacillus anthracis spores. "
05/01/2011 - "Infection was confirmed by blood culture and detection of anthrax toxin lethal factor (LF) in plasma. "
01/01/2015 - "An anthrax toxin variant with an improved activity in tumor targeting."
06/01/2013 - "Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen."
03/29/2013 - "Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors."
01/01/2011 - "Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors."
01/01/2010 - "The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin."
|4.||Human Influenza (Influenza)
|3.||anthrax toxin (anthrax lethal factor)
|9.||Immunoglobulin G (IgG)